Literature DB >> 2605671

Interaction of ellipticine and an indolo[2,3b]-quinoxaline derivative with DNA and synthetic polynucleotides.

I Zegar1, A Gräslund, J Bergman, M Eriksson, B Nordén.   

Abstract

The non-covalent DNA interaction of the anticancer drug ellipticine (Scheme I, 1a) as well as an indolo[2,3-b]-quinoxaline derivative (Scheme I, 3b) with a dimethylaminoethyl side chain has been studied by light absorption, linear dichroism (LD) and fluorescence. Compound 3b (Scheme I) has antitumorigenic as well as antiviral activity. Both compounds bind to DNA or synthetic polynucleotides such as poly(dA-dT).(dA-dT) and poly(dG-dC).(dG-dC) by intercalation. In contrast to ellipticine, compound 3b (Scheme I) exhibits a significant binding specificity for alternating AT sequences. Its fluorescence is strongly enhanced in AT sequences and quenched in GC sequences. Fluorescence titrations evaluated as Scatchard plots show that both ellipticine and compound 3b (Scheme I) bind to the nucleic acids according to a non-cooperative neighbor exclusion model.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2605671     DOI: 10.1016/0009-2797(89)90004-5

Source DB:  PubMed          Journal:  Chem Biol Interact        ISSN: 0009-2797            Impact factor:   5.192


  1 in total

1.  Preclinical antitumor efficacy of analogs of XK469: sodium-(2-[4-(7-chloro-2-quinoxalinyloxy)phenoxy]propionate.

Authors:  T H Corbett; P LoRusso; L Demchick; C Simpson; S Pugh; K White; J Kushner; L Polin; J Meyer; J Czarnecki; L Heilbrun; J P Horwitz; J L Gross; C H Behrens; B A Harrison; R J McRipley; G Trainor
Journal:  Invest New Drugs       Date:  1998       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.